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Introduction
Emergence of carbapemenases and their worldwide distri-
bution has worsens the clinical scenario of antibiotic resis-
tance in Gram-negative bacteria. Selective Digestive
Decontamination (SDD) has been used to prevent devel-
opment of nosocomial colonization and infections in ICU
patients. However, rectal colonization with multirresistant
bacteria is a serious concern with SDD. An effective ent-
eral antimicrobial treatment in this scenario is still lacking
and it might contribute to prevent systemic nosocomial
infections.
Objective
To assess the value of enteral paromomycin to deconta-
minate patients with rectal colistin and / or carbepeme-
nase resistant microorganisms colonization to prevent
the development of ICU nosocomial infections.
Methods
All consecutive patients admitted to the ICU from Octo-
ber 2011 to February 2015, expected to require tracheal
intubation for longer than 48 hours were given SDD with
a 4-day course of intravenous cefotaxime, plus enteral
colistin, tobramycin, nystatin in an oropharyngeal paste
and in a digestive solution. Oropharyngeal and rectal
swabs were obtained on admission and once weekly.
Patients with rectal swabs colonized by colistin and / or
carbepemenase resistant microorganisms were treated
with enteral paromomycin 1 gr every 6 hours daily, in
order to negativize it and eventually preventing nosoco-
mial infections. Categorical variables were summarized as
frequencies and percentages and the continuous ones
as medians and interquartile ranges (IQR) or means and
standard deviations. Statistical significance was set at
p ≤ 0.05.
Results
We applied paromomycin treatment to 39 patients colo-
nized with rectal colistin resistant microorganisms. All
of them had colonization by Extended Spectrum Beta-
lactamases (ESBLs) Klebsiella pneumoniae. Demographic
data and type of admission are shown in Figure 1.
Twenty nine (74.3%) out of 39 of the studied patients
negativized the rectal swab. Three of them (7.6%) were
colonized by carbepemenases producing microorganisms
and only one of them died with persistent multirresis-
tant rectal colonization. Only 9 out of the 29 patients
that negativized the colonization received concurrent
susceptible IV antibiotics. None of the patients treated
with paromomycin developed any infection including
ESBL Klebsiella pneumoniae. Finally, 13 patients died in
the ICU.
Conclusions
Our preliminary data show that enteral paromomycin is
useful in treating rectal colistin and / or carbepemenase
resistant microorganisms colonization to prevent the
development of ICU nosocomial infections.
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Figure 1 Patients data.
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